In specific types of breast cancer, high UCHL1 activity may be targeted to enhance the efficacy of endocrine therapy in estrogen receptor-negative breast cancer cells and slow migration and metastasis of triple-negative breast cancer (48, 49). This evidence concerns the gene UCHL1 and triple-negative breast carcinoma.